• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Hims & Hers

By: Faruqi & Faruqi, LLP via Business Wire
June 23, 2025 at 13:35 PM EDT

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Hims & Hers To Contact Him Directly To Discuss Their Options

If you suffered significant losses in Hims & Hers stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”) (NYSE: HIMS).

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

Shares of Hims & Hers Health fell over 25% on June 23 after Novo Nordisk announced it was terminating its partnership with the company, citing “deceptive marketing” and “illegal mass compounding” of semaglutide-based weight-loss treatments. The collaboration between the two healthcare companies launched in April, and allowed Hims to offer Wegovy through its telehealth platform. According to Novo Nordisk, Hims continued selling compounded versions of semaglutide even after the FDA determined that Novo Nordisk's Wegovy was no longer in shortage.

To learn more about the Hims & Hers investigation, go to www.faruqilaw.com/HIMS or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250623922129/en/

Contacts

Faruqi & Faruqi, LLP

Josh Wilson

877-247-4292 or 212-983-9330 (Ext. 1310)

More News

View More
Why the Precious Metal Nobody Talks About Could Be Your Best Bet
Today 14:43 EDT
Via MarketBeat
Topics ETFs Economy
Tickers PALL VOO
Cheap Chipotle? Why CMG Stock Could Be Ready for a Comeback
Today 12:46 EDT
Via MarketBeat
Tickers CMG YUM
3 Industrial Stocks Ready to Benefit From Fed Cuts and Spending
Today 11:34 EDT
Via MarketBeat
Topics Economy Stocks World Trade
Tickers CC DOW NUE
A Copper Catalyst: Why Freeport-McMoRan Is Positioned to Rebound
Today 10:44 EDT
Via MarketBeat
Topics Artificial Intelligence Economy
Tickers BAC FCX
MarketBeat Week in Review – 09/29 - 10/03
Today 7:00 EDT
Via MarketBeat
Topics Artificial Intelligence Economy
Tickers AAPL APP BBAI BYDDF COST CRWV
Recent Quotes
View More
Symbol Price Change (%)
GOOG  246.45
+0.02 (0.01%)
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap